Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation
Abstract
The aim of the study was to assess cardiac toxicity during myeloablative preparative regimen (PR) and hematopoietic cell transplantation (HCT) with biomarkers of cardiac injury: glycogen phosphorylase BB (GPBB), heart fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Nineteen patients (mean age 42.8+-10.0 years, 13 males) with acute leukemia were studied.
GPBB became elevated (above 7.30 ?g/L) in 5 (26.3%) patients after PR, remained elevated in 5 (26.3%) after HCT and in 1 (5.3%) 14 days after HCT. Other markers remained within the reference range in all patients.
Our findings suggest that GPBB released from cardiomyocytes after myeloablative PR followed by HCT could be a new marker of acute subclinical cardiotoxicity. The predictive value for development of cardiomyopathy is unclear and further studies will be needed in this context.